本页面由Tiger Trade Technology Pte. Ltd.提供服务

Cue Biopharma, Inc.

4.76
+1.9368.20%
盘后:4.790.0300+0.63%19:59 EST
成交量:1,322.89万
成交额:5,195.82万
市值:3,979.13万
市盈率:-0.18
高:4.77
开:3.41
低:3.27
收:2.83
52周最高:45.50
52周最低:2.83
股本:835.95万
流通股本:734.38万
量比:13.27
换手率:180.14%
股息:- -
股息率:- -
每股收益(TTM):-26.9925
每股收益(LYR):-8.4244
净资产收益率:-800.39%
总资产收益率:-174.18%
市净率:1.04
市盈率(LYR):-0.57

数据加载中...

2026/11/17

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/11/17

重要事件披露

Form 8-K - Current report
2026/11/17

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/11/16

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/11/16

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/11/11

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/10/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/10/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/10/08

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/09/21

重要事件披露

Form 8-K - Current report
2026/08/19

SEC问询函

Form CORRESP - Correspondence
2026/08/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/14

重要事件披露

Form 8-K - Current report
2026/08/14

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/04

重要事件披露

Form 8-K - Current report
2026/07/10

重要事件披露

Form 8-K - Current report
2026/06/30

SEC问询函

Form CORRESP - Correspondence
2026/06/16

SEC问询函

Form CORRESP - Correspondence